Zelgen Biopharmaceuticals (688266.SH) Receives $10 Million Milestone Payment from AbbVie for ZG006

Zhitong Finance APP News, Zelgen Biopharmaceuticals (688266.SH) announced that on December 30, 2025, the company entered into a strategic collaboration and license option agreement with AbbVie Group Holdings Ltd. (registered in Bermuda) (referred to as "AbbVie") for the global development and commercialization of ZG006 (Alveltamig). Following the execution of the above agreement, the company and AbbVie have actively advanced the subsequent development of ZG006. The company received the US$100 million upfront payment from AbbVie at the beginning of the year in accordance with the timetable stipulated in the agreement, and recently received a US$10 million near-term milestone payment from AbbVie based on clinical trial progress.